Traferox Technologies Receives FDA Premarket Approval for the TorEx Lung Perfusion System

Traferox Technologies has received FDA Premarket Approval for the TorEx Lung Perfusion System, an ex vivo lung perfusion platform that enables functional assessment of donor lungs outside the body before transplantation. The technology addresses a critical bottleneck: approximately 80% of donor lungs in the US are currently discarded due to assessment uncertainty, but TorEx has demonstrated that ~67% of marginal donor lungs can be safely transplanted after evaluation.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.